The study assessed several biomarkers, including CDKN2A, TNFRSFOB, BBC3, CCNG1, TRIAP1, CDKN1A, MDM2, FDXR, DDB2, XPC, EDA2R, RPS27L, and BAX, comparing MDM2 mRNA expression in patients to reference levels from others with the same cancer type [315]. The gene discussed is MDM2; the disease is cancer.